Revolution Medicines (RVMD) Amortization of Deferred Charges (2021 - 2026)
Revolution Medicines (RVMD) posted quarterly Amortization of Deferred Charges of $2.2 million for Q1 2026, up 24.59% year-over-year from $1.8 million in Q1 2025, and down 7.48% quarter-over-quarter from $2.4 million in Q4 2025.
Revolution Medicines (RVMD) Amortization of Deferred Charges (2021 - 2026) Analysis & Trends
Revolution Medicines' Amortization of Deferred Charges history runs 6 years deep, the most recent figure standing at $2.2 million for Q1 2026.
- In Q1 2026, Amortization of Deferred Charges rose 24.59% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $8.3 million (up 66.9% YoY), while the FY2025 annual figure was $7.9 million, up 88.47% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $2.2 million, down from $2.4 million in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $2.4 million in Q4 2025, with the low at $283000.0 in Q2 2023.
- The 5-year median for Amortization of Deferred Charges is $1.2 million (2022), against an average of $1.3 million.
- The sharpest annual moves came in 2023 and 2024: Amortization of Deferred Charges slumped 75.09% in 2023, then jumped 213.78% in 2024.
- Revolution Medicines' Amortization of Deferred Charges stood at $1.2 million in 2022, then climbed by 5.25% to $1.2 million in 2023, then gained by 11.33% to $1.4 million in 2024, then jumped by 70.83% to $2.4 million in 2025, then slipped by 7.48% to $2.2 million in 2026.
- Business Quant data shows RVMD's Amortization of Deferred Charges at $2.2 million in Q1 2026, $2.4 million in Q4 2025, and $2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.05 Mn |
| Jun 30, 2026 | 2.05 Mn |
| Mar 31, 2026 | 2.19 Mn |
| Mar 31, 2026 | 2.19 Mn |
| Dec 31, 2025 | 2.37 Mn |
| Dec 31, 2025 | 2.37 Mn |
| Sep 30, 2025 | 2.01 Mn |
| Sep 30, 2025 | 2.01 Mn |
| Jun 30, 2025 | 1.78 Mn |
| Jun 30, 2025 | 1.78 Mn |
| Mar 31, 2025 | 1.76 Mn |
| Mar 31, 2025 | 1.76 Mn |
| Dec 31, 2024 | 1.39 Mn |
| Dec 31, 2024 | 1.39 Mn |
| Sep 30, 2024 | 967,000.00 |
| Sep 30, 2024 | 967,000.00 |
| Jun 30, 2024 | 888,000.00 |
| Jun 30, 2024 | 888,000.00 |
| Mar 31, 2024 | 956,000.00 |
| Mar 31, 2024 | 956,000.00 |